CD19 CAR T cell product and disease attributes predict leukemia remission durability
耐久性
医学
疾病
白血病
肿瘤科
内科学
免疫学
癌症研究
计算机科学
数据库
作者
Olivia Finney,Hannah Brakke,Stephanie D. Rawlings‐Rhea,Roxana Hicks,Danielle Doolittle,M. I. Esteban López,Ben Futrell,Rimas J. Orentas,Daniel Li,Rebecca Gardner,Michael C. Jensen
BACKGROUND. Chimeric antigen receptor (CAR) T cells can induce remission in highly refractory leukemia and lymphoma subjects, yet the parameters for achieving sustained relapse-free survival are not fully delineated.